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doi:10.1016/j.ejvs.2008.11.030Abstract Objective: To evaluate whether low-molecular-weight heparin (LMWH) could be
equally (or more) effective than oral anti-vitamin-K agents (AVK) in the long-term treatment
of deep venous thrombosis (DVT).
Design: A randomised, open-label trial.
Material and methods: In this trial, 241 patients with symptomatic proximal DVT of the lower
limbs confirmed by duplex ultrasound scan were included. After initial LMWH, patients
received 6 months of treatment with full therapeutic dosage of tinzaparin or acenocoumarol.
The primary outcome was the 12-month incidence of symptomatic recurrent venous thrombo-
embolism (VTE). Duplex scans were performed at 6 and 12 months.
Results: During the 12-month period, six patients (5%) of 119 who received LMWH and 13 (10.7%) of
122 who received AVK had recurrent VTE (pZ 0.11). In patients with cancer, recurrent VTE tended
to be lower in the LMWH group (two of 36 [5.5%]) vs. seven of 33 [21.2%]; pZ 0.06). One major
bleeding occurred in the LMWH group and three in the AVK group. Venous re-canalisation increased
significantly at 6 months (73.1% vs. 47.5%) and at 12 months (91.5% vs. 69.2%) in the LMWH group.260 7665.
.es (A. Romera).
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350 A. Romera et al.Conclusions: Tinzaparin was more effective than AVK in achieving re-canalisation of leg thrombi.
Long-term tinzaparinwas at least as efficacious and safe as AVK for preventing recurrent VTE, espe-
cially in patients with cancer.
Crown Copyright ª 2008 Published by Elsevier Ltd on behalf of European Society for Vascular
Surgery. All rights reserved.Low-molecular-weight heparin (LMWH) has a number of
theoretical advantages over oral-anticoagulant therapy.
Compared to vitamin-K antagonists, LMWH has more stable
pharmaco-kinetic properties and fewer drug interactions.1
Consequently, weight-based dosing of this agent produces
a predictable anticoagulant effect that does not require
routine laboratory monitoring.
TheroleofLMWHasanalternative tooral anticoagulation in
the outpatient DVT treatment for the prevention of recurrent
venous thrombo-embolism (VTE) has beenevaluated in several
clinical trials.2e8 These trials primarily included patients
without cancer and used prophylactic doses of LMWH for
extendedtreatment rather than full therapeuticdoses thatare
used for the initial treatment of VTE.
A systematic evaluation of these studies found a non-
significant reduction in the risk of recurrent VTE in favour
of LMWH and concluded that there is little evidence to
suggest whether long-term LMWH treatment is as effective
as vitamin-K antagonist treatment.9 The authors observed
that the prophylactic LMWH doses used in some of these
trials may have resulted in inadequate therapy.6,8
Subsequently, several clinical trials showed that long-
term LMWH was more effective than anti-vitamin-K agents
(AVK) for preventing recurrent VTE without increased
bleeding10e13 and it is now recommended in most interna-
tional guidelines.14 Whether this benefit applies to other
patient groups with deep vein thrombosis (DVT) is uncer-
tain. Because of the uncertainty, vitamin-K antagonist
treatment is still the treatment of choice in the prevention
of recurrent symptomatic VTE.8 However, majority of
previous investigations that compared long-term LMWH
with oral anticoagulants did not use ultrasonographic end-
points, leading to questions about the resolution of thrombi
and the prevention of valve insufficiency.15
We conducted a randomised, open-label clinical trial in
patients with acute DVT to evaluate clinical efficacy as well
as the resolution of thrombi with long-term therapeutic
doses of tinzaparin compared with the usual care consisting
of tinzaparin and long-term acenocoumarol.
Patients and Methods
Study design
We conducted an open-label prospective randomised clin-
ical trial to compare sub-cutaneous LMWH (tinzaparin)
administered for 6 months with initial treatment using sub-
cutaneous LMWH followed by oral anticoagulants given for
a similar period of time in patients with proximal venous
thrombosis. Two centres in Spain participated in the trial.
The protocol was approved by the institutional review board
at each centre and by the regulatory authorities. Written,
informed consent was obtained from all patients. Theprimary outcomemeasurements were those of the incidence
of first episode of objectively documented symptomatic DVT
or pulmonary embolism at 6 months and 1 year.
Patient selection
Consecutive, symptomatic patients of either sex and over
18 years of age, who had been referred to the Vascular
Surgery Department of the hospital with a first episode of
acute proximal-vein thrombosis of the lower limbs (onset of
symptoms less than 2 weeks) documented by compression
ultrasonography, were enrolled in the study from January
2002 to January 2005.
Patients were excluded if they had any of the following
conditions: pulmonary embolism requiring thrombolytic
therapy, surgical thrombectomy or vena cava interruption,
contraindication to anticoagulant treatment (active
bleeding, severe blood pressure or allergy to the study
drugs), platelet count lower than 100 103 ml1 or hae-
moglobin concentration lower than 7 g dl1, severe renal
failure necessitating dialysis, pregnancy; a history of
heparin-associated thrombo-cytopenia; surgery within the
previous 14 days, lumbar puncture within the previous 24 h
and those receiving oral-anticoagulant treatment or anti-
platelet drugs for other conditions unable to discontinue
this medication during the treatment interval. Eligible
patients were excluded if they had received heparin, LMWH
or oral-anticoagulant therapy for more than 2 days.
Treatment
All patients were given tinzaparin (innohep, LEO Pharma
A/S) sub-cutaneously in a fixed dose of 175 IU anti-Xa per kg
of body weight once daily. The patients randomised to
tinzaparin received this regimen for 6 months without
dosage adjustments. The patients randomised to oral
anticoagulants were given 3 mg of acenocoumarol orally
which was subsequently adjusted to achieve a regular
international normalised ratio (INR) of between 2 and 3 for
6 months. In these patients, tinzaparin was given until the
INR reached at least 2 on two consecutive measurements.
Thereafter, INR monitoring was performed by the haema-
tologists every month until completion of therapy.
Duplex ultrasonography
Diagnosis was established by duplex ultrasonography using
linear array 5e10 MHz (ATL-Ultramark 5000 and Aloka
6000). The deep veins were examined using compression by
the transducer on B-mode in the cross-sectional view.
Colour flow was used to detect luminal feeling defects and
Doppler tracings were also obtained. Diagnosis was estab-
lished by using the following ultrasound criteria: (1) no
Treatment of Deep Venous Thrombosis 351collapse or partial collapse of the vein lumen at transducer
compression; (2) thrombus visualisation within vein lumen;
(3) absence of spontaneous venous flow; (4) absence of
Doppler signal and (5) increase in vein diameter.
At least two of the above criteria had to be present
before a diagnosis of DVT was made.
The compression method was used to assess thrombus
resolution. The vein segment under examination was classi-
fied as ‘totally re-canalised’ when it was compressible with
gentle transducer pressure and showed normal flow with
colour-flow imaging; ‘re-canalised’ if the vein wall could be
approximated, even if not completely, and flow was evident
with colour-flow imaging and ‘occluded’ if the segment could
not be compressed at all, with high echoes in the lumen,
irregular thick wall and with no flow on colour-flow imaging.
Follow-up and surveillance
All patients were instructed to come to the hospital
immediately if they had symptoms or signs suggestive of
recurrent DVT, pulmonary embolism or bleeding. All
patients who were presented with symptoms or signs of
recurrent VTE underwent ultrasonography. In addition,
a thorough clinical examination, as well as an ultrasound
assessment of the venous system of both lower limbs was
performed on all patients who attended routine visits to the
clinic at 1, 6 and 12 months after entry.
All objective diagnostic tests were interpreted by special-
ists who were not involved in the study. The haematologists
were responsible for monitoring the oral-anticoagulation
therapy. The vascular surgeon, who performed the serial
duplex scan, did not know the treatment allocation. D-dimer
testing (IL test D-dimer on the ACL 9000 automated coagula-
tion analyser) was performed at baseline and about a month
after the patients completed 6 months of therapy with tin-
zaparin or acenocoumarol. D-dimer values above 235 ngml1
were classified as abnormal.
Clinical assessments
The primary outcome measurements were the first episode of
objectively documented symptomatic DVT or pulmonary
embolismat 6months and1 year. Recurrent venous thrombosis
was diagnosed when a previously compressible proximal-vein
segment or segments were no longer compressible on ultra-
sonography. In patients with clinically suspected pulmonary
embolism, the diagnosis was confirmed by a high-probability
lung scan finding, an abnormal perfusion scan with docu-
mented new DVT or a spiral CT scan showing thrombus in the
pulmonary arteries.
The primary safety endpoint was the occurrence of major
bleeding during the 6-month treatment interval. Bleeding
was classified as major if it was overt and associated with
a fall in the haemoglobin level of 2 g dl1 ormore, resulted in
the transfusion of two or more units of blood, was retro-
peritoneal, occurred into a major joint or was intra-cranial.
Statistical analysis
A sample size of 121 patients in each treatment group was
initially chosen to provide 80% power for a two-sided test(aZ 0.05) to detect a 14% reduction in recurrences from
the 11% experienced in a previous trial.
Baseline comparability was assessed by the tabulation of
patient characteristics. All study data were summarised by
means of appropriate descriptive statistics. The following
tests were used to compare treatment groups at baseline:
Fisher’s exact test for categorical variables, Student’s
t-test for continuous variables and ManneWhitney test for
ordinal variables. The KaplaneMeyer method was used to
estimate the survival function for time-to-event variables
and the log-rank test was used to compare both treat-
ments. A multivariate step-wise regression model was used
to identify independent variables that could influence the
percentage of recurrences of DVT in both groups. The
analysis was performed using SPSS v.11, and the level of




The study population consisted of 241 consecutive patients,
who were recruited from two centres and randomised to
either LMWH therapy sub-cutaneously (119 patients) or
LMWH followed by acenocoumarol (122 patients). The
groups were comparable at entry (Table 1). The groups
were also similar with respect to the likely aetiology of
their DVT. Two patients from each group died during the
follow-up period due to cancer. The rest of the patients
randomised and completed the 12-month protocol
successfully.
Recurrent VTE
Five of 119 patients (4.2%) receiving LMWH and seven of 122
patients (5.7%) receiving LMWH followed by acenocoumarol
had new symptomatic, objectively documented venous
thrombo-embolic events during the 6-month treatment
interval (pZ 0.6). Two patients (one from each group) who
developed symptoms of pulmonary embolism on the same
day of randomisation were also included in the analysis. At
the completion of 1 year, six patients assigned to LMWH
(5%) and 13 patients assigned to LMWH and acenocoumarol
(10.65%) had new episodes of symptomatic VTE docu-
mented by objective testing (pZ 0.11; 95% CI: e12.4% to
1.1%) (Table 2, Fig. 1a). A patient in the AVK group had two
recurrences on days 6 and 300, but only the first event was
considered for this analysis.
In the cancer population, two patients receiving LMWH
(5.5%) and three patients receiving LMWH followed by
acenocoumarol (9.1%) had new episodes of VTE during the
6-month treatment interval (pZ 0.58; 95% CI: 15.9% to
8.8%). At 1 year (Fig. 1b), two patients in the LMWH group
(5.5%) and seven patients in the LMWH followed by long-
term acenocoumarol group (21.2%) had new episodes of
symptomatic VTE (pZ 0.06; 95% CI: 31.5% to 0.17%).
Sub-analysis of recurrent VTE after the treatment period
(Fig. 1a) showed that one patient who received LMWH
(0.85%) and seven patients who received acenocoumarol
(5.7%) had new episodes of VTE up to 1 year (pZ 0.03; 95%
Table 1 Clinical characteristics of patients with proximal venous thrombosis treated with long-term low-molecular-weight
heparin or oral-anticoagulant therapy
Characteristic All patients Patients with cancer
Acenocoumarol LMWH Acenocoumarol LMWH
NZ 122 NZ 119 N Z 33 NZ 36
No. of patients (%) No. of patients (%)
Age (year SD) 61.3 16.2 58.9 17.6 64.7 15.2 59.8 15.5
Sex (M, %) 70 (57.4) 64 (53.8%) 20 (60.6) 18 (50)
Risk factors
Thrombophilia 11 (9%) 11 (9.2%) 4 (12.1) 5 (13.9)
Cancer 33 (27%) 36 (30.3%)
Bedridden 34 (27.9%) 43 (36.1%) 8 (24.2) 12 (33.3)
Traumatism 14 (11.5%) 18 (15.1%) 0 (0.0) 2 (5.6)
Surgery 8 (6.6%) 11 (9.2%) 3 (9.1) 5 (13.9)
Oral contraception 6 (4.9%) 10 (8.4%) 0 (0.0) 2 (5.6)
Status at entry
Iliofemoral 22 (18%) 12 (10.1%) 12 (36.4) 4 (11.1)
Femoro-popliteal 72 (59%) 80 (67.2%) 16 (48.5) 28 (77.8)
Popliteal 28 (23%) 27 (22.7%) 5 (15.1) 4 (11.1)
D-dimer (median) 868 (244e13,460) 860 (275e9942) 1050 (430e13,460) 1040 (303e9942)
Last D-dimera (median) 253 (100e1678) 240 (110e1672) 490 (190e1563) 420 (110e1672)
Last D-dimer <235 54 (45.8%) 53 (49.5%) 7 (21.2%) 8 (25.8%)
Time of evolution
<48 h 30 (24.6) 31 (26.1) 12 (36.4) 12 (33.3)
3e7 days 70 (57.4) 66 (55.5) 16 (48.5) 22 (61.1)
>7 days 22 (18) 22 (18.5) 5 (15.1) 2 (5.6)
a Last D-dimer was measured 30 days after treatment. Data are missing in 16 patients (four in the AVK group and 12 in the LMWH
group).
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the sub-group of 69 patients with cancer (0% vs. 15.16%;
pZ 0.015; 95% CI: 7.6% toe0.58%).
Analysis of risk factors for DVT
From the univariate analysis of the demographic and
medical characteristics listed in Table 3 the age was asso-
ciated with greater odds of DVT and the reduction of D
Dimer with lower odds of DVT. In contrast, the venous
segment affected, the time of evolution or the D-dimer
level after treatment was not associated with recurrence.
Excluding the DVT that occurred in the first 12 days, while
both groups were treated with LMWH, the factors associ-
ated with greater odds of DVT were cancer (4.4, 95% CI:
1.02e18.9; 0.047), previous surgery (8.1, 95% CI: 1.78eTable 2 Recurrent venous thrombo-embolism
6 Months
LMWH NZ 119 LMWH/AVK
New episodes of PE 4 (3.4%) 3 (2.5%)
Recurrent DVT 1 (0.8%) 4 (3.3%)
Total recurrent VTEa 5 (4.2%) 7 (5.7%)
a There was a trend in the reduction of recurrences of DVT at 12
pZ 0.15).37.16; 0.007) and the lower reduction of D-dimer (1.0002,
95% CI: 1.0001e1.0003; 0.006). There was a tendency of
higher risk of DVT in patients treated with AVK (7.18, 95%
CI: 0.87e59.3; 0.07).
In the multivariate analysis, the risk factors indepen-
dently associated with greater odds of DVT were the age of
the patient and a lower reduction of D-dimer from baseline.
Clinical examination
In both groups, response to treatment was good and reso-
lution of symptoms and clinical signs was quick. This was
noticeable from the first re-evaluation after 1 month of
therapy. On completion of the treatment period, the clin-
ical appearance was similar in the LMWH and AVK groups:
oedema (13.4% vs. 13.9%), local tenderness or pain (0% vs.1 Year
NZ 122 LMWH NZ 119 LMWH/AVK NZ 122
4 (3.4%) 3 (2.5%)
2 (1.7%) 10 (8.2%)
6 (5.0%) 13 (10.7%)
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Figure 1 (a) Cumulative incidence of recurrent venous
thrombo-embolism in the treatment groups. There was a non-
significant reduction in the recurrence of venous thrombo-
embolism in the tinzaparin group as compared with the oral-
anticoagulant group (log-rank test pZ 0.11). Estimates after
cessation of the anticoagulant treatment (day 180) in the
treatment groups. There was a significant reduction in the
tinzaparin group (log-rank test pZ 0.03). (b) KaplaneMeier
estimates the probability of recurrent venous thrombo-embo-
lism in patients with cancer in the treatment groups. There was
a non-significant reduction in the tinzaparin group (log-rank
test pZ 0.06). Excluding the patients with symptoms of
pulmonary embolism that occurred on the day of random-
isation (one per group) the difference was significant (log-rank
test pZ 0.018).
Treatment of Deep Venous Thrombosis 3531.6%), respectively. No fractures or symptoms of severe
osteoporosis were reported during the treatment period.
Degree of thrombus regression
We compared the ultrasound changes between treatment
groups at baseline, at 6 months and upon conclusion of the
observation phase (1 year). Differences in complete reso-
lution of the clot were observed after 6 months (58e47.5%
vs. 87e73.1%; p< 0.001) and 12 months (83e69.2% vs. 107e
91.5%; p< 0.001) between AVK and LMWH groups, respec-
tively. A comparison of these findings is presented in
Table 4, which shows the advantage of tinzaparin over
acenocoumarol.
The ultrasound assessment of the whole sample at 6
months showed that five (5.2%) of 96 patients with incom-
plete re-canalisation and three (2.1%) of 145 with complete
re-canalisation developed a new DVT after cessation ofanticoagulant treatment (pZ 0.27). None of the 71
patients with complete re-canalisation and low D-dimer
level exhibited new DVT after discontinuation of anticoag-
ulant (0% vs. 5.2%; pZ 0.11).
The affected limbs were examined for the presence of
venous reflux in 116 patients in the AVK group and 117
patients in the LMWH group as part of routine ultrasound
scanning at 12 months. Veins were considered to be
competent in 22 (19%) patients in AVK and in 69 (59%)
patients in LMWH groups, respectively (p< 0.001).
Bleeding
Three of 122 patients in the AVK group (2.5%) and one of
119 patients who received tinzaparin (0.8%) had major
bleeding (pZ 0.6). Major bleeding was associated with an
INR of more than 3.0 in two patients in the AVK group.
There were no fatal bleeding events. Minor bleeding events
were not registered.
Discussion
This study indicates that after initial short-term manage-
ment with LMWH, long-term LMWH is, at least, as effective
as long-term vitamin-K antagonist therapy in patients with
acute proximal venous thrombosis. It is possible that with
a larger sample size, the difference may achieve statistical
significance. The findings of our study are supported by
previous research and the literature.2e8,15,16
The possible advantage of tinzaparin over AVK dis-
appeared when we analysed the patients without cancer.
The meta-analyses of a number of small studies that
included, primarily, patients without cancer and used
prophylactic doses of LMWH for extended treatment rather
than full therapeutic doses found a non-significant reduc-
tion of approximately 30% in the risk of recurrent VTE
favouring LMWH.9,17 A more recent and larger study also
failed to find a significant difference between LMWH given
at full dose and AVK.18 Overall, LMWH does not appear to
offer any measurable efficacy or advantage over standard
treatment with AVK in patients without cancer.
The statistically significant difference favouring LMWH
over AVK in all patients receiving treatment comes mostly
from studies10e13 that included cancer patients. In our
study, time-to-event analysis in patients with cancer,
identified at the time of entry, also suggests that long-term
LMWH may be more effective than traditional therapy. We
cannot rule out that the two patients (one from each group)
who developed symptoms of pulmonary embolism on the
day of randomisation were new occurrences. When we
excluded these recurrences from the analysis, the differ-
ences between groups in the cancer population reached
statistical significance.
It has been reported18 that patients treated with long-
term LMWH have recurrent events earlier after cessation of
therapy compared with AVK, even though persistent
excessive VTE events (true rebound) do not occur.18,19 The
results could in part be due to the different proportion of
patients in the two groups who received prolonged treat-
ment beyond 3 months without a standardisation of treat-
ment duration after the initial 3 months. In addition, the
Table 3 Univariate associations between medical characteristics and recurrence of venous thrombo-embolism
Characteristic Patients DVT n (%) Odds ratio (95% CI) p-Value
Age (year SD) 60.1 SD 16.9 19 1.038 (1.0004e1.077) 0.0478
Sex
Female 107 8 (7.5) 1.00 0.83
Male 134 11 (8.2) 1.107 (0.43e2.86)
Risk factors
Thrombophilia
No 219 17 1.00 0.82
Yes 22 2 1.19 (0.26e5.52)
Cancer
No 172 10 1.00 0.066
Yes 69 9 2.43 (0.94e6.27)
Bedridden
No 164 11 1.00 0.33
Yes 77 8 1.61 (0.62e4.19)
Trauma
No 209 15 1.00 0.305
Yes 32 4 1.85 (0.57e5.96)
Surgery
No 222 16 (7.2) 1.00 0.19
Yes 19 3 (15.8) 2.41 (0.63e9.16)
Status at entry
Venous segment
Popliteal 55 5 1.00 0.88
Iliofemoral 34 3 0.97 (0.22e4.33)
Femoral 152 11 0.78 (0.26e2.36)
Last D-dimer 407 496 225 1.0001 (0.9993e1.0009) 0.84
Reduction D-dimer 1474 3000 225 0.999 (0.9998e1.00) 0.018
Time of evolution
>7 days 44 (18.3) 5 (11.4) 1.00 0.33
<48 h 61 (25.3) 3 (4.9) 1.086 (0.174e6.79)
3e7 days 136 (56.4) 11 (8.1) 2.41 (0.53e11.05)
Treatment
Tinzaparin 119 6 1.00
Acenocoumarol 122 13 2.25 (0.82e6.12) 0.11
Table 4 Ultrasound changes between treatment groups at 6 months and upon conclusion of the observation phase
6 Months 1 Yeara
LMWH NZ 119 AVK NZ 122 LMWH NZ 117 AVK NZ 120
Thrombus regressionb Complete 87 (73.1%) 58 (47.5%) 107 (91.5%) 83 (69.2%)
Incomplete 32 (26.9%) 64 (52.5%) 10 (8.5%) 37 (30.8%)
Degree of occlusionc Occluded 2 (1.7%) 5 (4.1%) 1 (0.8%) 2 (1.7%)
Severe 1 (0.85%) 1 (0.8%) 0 (0%) 0 (0%)
Moderate 3 (2.5%) 21 (17.2%) 2 (1.7%) 9 (7.5%)
Mild 26 (21.85%) 37 (30.3%) 7 (6.0%) 26 (21.6%)
Total re-canalisation 87 (73.1%) 58 (47.6%) 107 (91.5%) 83 (69.2%)
a Four patients died before the ultrasound evaluation.
b Regression of the thrombus was different in the LMWH than in the AVK group at 6 and 12 months, respectively (Fisher’s exact test
p< 0.001).
c Total re-canalisation was more frequent in the LMWH group than in the AVK group at 6 and 12 months (chi-square test p< 0.001).
Grouping total re-canalisation and mild occlusion, differences were statistically significant at 6 months (Fisher’s exact test p< 0.01), but
there was only a trend at 12 months (Fisher’s exact test pZ 0.051).
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Treatment of Deep Venous Thrombosis 355possibility that very low LMWH doses used in some trials for
the long-term treatment of symptomatic VTE should also be
taken into account.19 With these differences in the clinical
trials, it is difficult to extract a uniform clinical conclusion
from these studies. However, our findings after 6 months of
treatment showed a significant (pZ 0.03) excess of recur-
rent symptomatic VTE outcomes during follow-up in the
AVK group compared with LMWH.
A possible drawback is that a double-blind study was not
feasible due to the different routes of administration of the
two drugs and the need for regular dose adjustment in the
AVK group. However, the ultrasonographic evaluations were
performed blindly.
This study also showed that not only can tinzaparin be
used safely and effectively to treat DVT at home over the
long term but also that its ability to re-open thrombosed
veins is better than that of acenocoumarol. A higher degree
of re-canalisation was shown with ultrasonography in the
patients assigned to undergo LMWH therapy as compared
with the patients assigned to undergo treatment with
coumarin. These results are in concordance with other
published studies where thrombus regression was more
prominent in the LMWH group.2,8,15 The percentage of
patients with complete and substantial re-canalisation in
the AVK group was at least similar to other studies.2,5,8,15,16
In fact, both therapeutic regimens were proved to be
effective in preventing progression of thrombi and allowing
re-canalisation of the affected veins. However, thrombol-
ysis appears more extensively in the LMWH than in the AVK
group. It is interesting to note that the incomplete re-
canalisation after 6 months of treatment with D-dimer
levels increased and was likely to be associated with
recurrence of DVT. This finding could have therapeutic
implications in the management of the disease.20,21
The improved re-canalisation could explain, partly, the
difference of recurrence of DVT after treatment between
both groups. Cancer is also another factor that could
explain this excess of recurrence in the AVK group. In other
study, the incidence of DVT was higher in the AVK group
after treatment period.12 In addition, when we excluded
the patients with cancer in our study, we did not find any
difference. Whether the use of full LMWH dose for the
whole treatment period in patients with cancer had any
influence in the percentage of recurrence after treatment
needs to be confirmed.
We also found that earlier re-canalisation resulted in
less valve incompetence. Reflux in the veins was signifi-
cantly different when comparing the two treatments. This
is in agreement with other authors who demonstrated
a significantly lower rate of reflux in the veins of patients
treated with LMWH,8 but different from others.15 Our
findings, although the sample size was not sufficient,
suggest that LMWH may reduce the risk of late recurrence
after treatment in the 6-month follow-up period. It also
suggests that LMWH may reduce the risk of the late
sequelae of DVT. However, in our population, without
previous history of ipsilateral DVT, the 12-month follow-up
period used in this study is too short to reflect the true
development of clinical post-thrombotic syndrome.22
Since the majority of proximal DVTs require a 6-month
therapy, we excluded distal DVTs from our study that might
respond to a shorter therapy. In addition, we examined theperiod after cessation of the therapy. To our knowledge,
only four randomised trials used LMWH for 6
months.8,11,13,15 In two studies that included cancer
patients only, there was no follow-up after the treatment
period.11,13 In other two studies with a follow-up period till
1 year, LMWH was administered for 6 months8,15; however,
only in one of them the initial dosage of LMWH was main-
tained during the whole study.15 Results from these studies
were in favour of LMWH.
In conclusion, our study suggests that a single fixed dose
of tinzaparin administered at full therapeutic dosage for
a period of 6 months is at least as effective and safe as the
usual AVK treatment for preventing recurrent VTE. Sub-
analysis shows that tinzaparin is preferred in patients with
cancer along with VTE.11,12 Tinzaparin with a sub-cutaneous
injection once daily is more effective than AVK in achieving
re-canalisation of veins affected by thrombus.
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